Accuray Incorporated (USD) Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

Accuray Incorporated (USD) Active

1240 Deming Way, Madison, WI, US, 53717-1954

Stock Price USD

Price Change

Last Dividend USD

C+

Latest Rating

ARAY's stock peer is ANIK (Anika Therapeutics, Inc.)

ARAY's stock peer is AORT (Artivion, Inc.)

ARAY's stock peer is APYX (Apyx Medical Corporation)

ARAY's stock peer is AVNS (Avanos Medical, Inc.)

ARAY's stock peer is AXGN (AxoGen, Inc.)

ARAY's stock peer is AZYO (Aziyo Biologics, Inc.)

ARAY's stock peer is BVS (Bioventus Inc.)

ARAY's stock peer is CLPT (ClearPoint Neuro, Inc.)

ARAY's stock peer is CTSO (Cytosorbents Corporation)

ARAY's stock peer is CUTR (Cutera, Inc.)

ARAY's stock peer is FNA (Paragon 28, Inc.)

ARAY's stock peer is INVO (INVO Bioscience, Inc.)

ARAY's stock peer is KIDS (OrthoPediatrics Corp.)

ARAY's stock peer is NPCE (NeuroPace, Inc.)

ARAY's stock peer is NUVA (NuVasive, Inc.)

ARAY's stock peer is OFIX (Orthofix Medical Inc.)

ARAY's stock peer is SGHT (Sight Sciences, Inc.)

ARAY's stock peer is SIBN (SI-BONE, Inc.)

ARAY's stock peer is SRDX (Surmodics, Inc.)

ARAY's stock peer is TELA (TELA Bio, Inc.)

Healthcare Medical - Specialties

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

20%

Dcf Rating

60%

Return On Equity

80%

Return On Assets

20%

Debt To Equity

20%

Price To Earnings

40%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Recent News

Accuray to Participate in the Jefferies Global Healthcare Conference 2025

MADISON, Wis. , May 29, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Jefferies Global Healthcare Conference 2025.

2025-05-29 19:30:00

Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025

More than 40 Clinical Studies Using Accuray Technology Presented at ESTRO 2025; Company Highlights Innovation and Educational Symposia MADISON, Wis. , May 7, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting reinforces the benefits of the company's CyberKnife ® System in the treatment of prostate cancer at multiple stages of the cancer journey.

2025-05-07 07:35:00

Accuray Announces First SRS/SBRT Patient Treatments in Austria With the CyberKnife® System

Medical Team's Use of Accuray CyberComm™ Reduced Commissioning Time by Approximately 50 Percent*, Enabling Them to Initiate Patient Treatments Sooner MADISON, Wis. , May 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the CyberKnife® Center Salzburg is the first in Austria to treat patients with the CyberKnife ® System, expanding access to stereotactic radiosurgery (SRS) and ultra-hypofractionated stereotactic body radiation therapy (SBRT), treatment processes necessitating an extremely high degree of precision and accuracy.

2025-05-05 16:10:00

Accuray Reports Fiscal 2025 Third Quarter Financial Results

MADISON, Wis. , April 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third quarter ended March 31, 2025.

2025-04-30 16:05:00

Accuray CyberKnife® Platform Featured in New Studies Showcasing its Benefits in Central Nervous System Tumors Presented at Radiosurgery Society Scientific Meeting

Data Also Highlights Continued Clinical Advances Using the CyberKnife System That are Making High Quality Care an Option for People Who Previously Had Limited Choices MADISON, Wis. , April 3, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data on the clinical use of the CyberKnife ® System reinforce the device's broad-based radiation treatment capabilities for central nervous system (CNS) tumors.

2025-04-03 07:35:00

Accuray to Participate at 37th Annual Roth Conference

MADISON, Wis. , March 12, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced its participation in the 37th Annual Roth Conference taking place on March 16 -18, 2025 in Dana Point, California.

2025-03-12 07:30:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions